For nearly three decades, FOXKISER has developed and executed strategies that have enhanced the value of products and businesses in the biomedical and health field. FOXKISER offers strategic collaboration and counseling to a select group of clients operating at the intersection of law, science, medicine and public policy.
University of Pennsylvania
In February 2009 REGENX Biosciences entered into a worldwide, exclusive license and other agreements with the University of Pennsylvania in order to establish REGENX as a company that could focus on enabling the broad development of NAV technology.
In April 2014 REGENX announced that the company has entered into an agreement with AAVLife for the development and commercialization of
products to treat Friedreich’s ataxia (FA) using NAV technology.
In April 2014 REGENX and AveXis, Inc. announced that they have entered into an exclusive agreement for the development and commercialization of products to treat Spinal Muscular Atrophy (SMA) using NAV rAAV9 vectors.
Asklepios BioPharmaceutical, Inc.
In March 2012 REGENX Biosciences entered into an agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of products to treat Hemophilia A using NAV rAAV8 vectors.
Ariad Pharmaceuticals, Inc.
In April 2011 REGENX Biosciences announced an exclusive license agreement with ARIAD Pharmaceuticals, Inc. for its ARGENT™ gene expression regulation technology. This license expands the market applications for NAV Technology in therapeutic areas where there is a need for precise calibration of pharmacologic control of gene expression.
Audentes Therapeutics, Inc.
In July 2013 REGENX Biosciences announced an exclusive license agreement with Audentes Therapeutics, Inc. for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease using NAV vectors.
In October 2013 Fidelity Biosciences and REGENX announced the formation of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension will focus on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for AAV therapeutics.
In March 2014 REGENX and ESTEVE announced that they have entered into an agreement enabling the development and commercialization of products to treat mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome TypeA) using NAV rAAV9.
In March 2009 REGENX Biosciences entered into a worldwide license agreement with GlaxoSmithKline (GSK) in order to secure the exclusive research, development, and commercial rights to key intellectual property covering NAV vectors. From 2001-2008, GSK supplied sponsored research funding to the lab of James M. Wilson, M.D., Ph.D. at the University of Pennsylvania that yielded many of the discoveries of NAV vectors.
In December 2013 REGENX and LYSOGENE announced that they have entered into an agreement enabling the development and commercialization of products to treat mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A) using NAV rAAVrh10.
UCL (University College of London)
The UCL Institute of Ophthalmology is one of a number of specialized research centers linked to UCL (University College London) and is, together with Moorfields Eye Hospital, one of the leading centers for eye research.Over the past ten years researchers at UCL have been at the forefront of investigating the basic aspects of gene transfer to the eye with a broad program of work to develop gene therapy for eye disease and in particular for disorders affecting the retina, including inherited retinal degeneration as well as complex diseases such as those associated with retinal and choroidal neovascularisation and posterior uveitis.
The Telethon Institute of Genetics and Medicine
TIGEM was created by Telethon Foundation of Italy to promote the advancement of research aimed at the diagnosis, prevention and cure of human genetic diseases. TIGEM's mission is to understand the mechanisms of genetic diseases and to develop therapeutic and preventive strategies. The scope of the science currently covered at TIGEM includes developmental disorders, inherited eye diseases and inborn errors of metabolism. Research approaches involve molecular genetics, cell biology, protein biochemistry, transgenic mice, bioinformatics, functional genomics, systems biology and gene therapy.